☰
Ovarian cancer is termed as fifth most common cause of cancer-related death among women in the U.S. It can mostly be treated by surgery or chemotherapy; however, several biotech companies are now making some groun...
Read More >>Type-2 diabetes is classified as a chronic condition that impacts the body’s way of processing blood sugar or glucose. Currently, the condition can be regulated using exercise, diet, insulin therapy and medicatio...
Read More >>Metastatic pancreatic cancer (MPC) is one of the most fatal cancers in the world. Pancreatic cancer is slated to be the third leading cause of cancer death in the U.S. and is expected to become the second leading cause...
Read More >>Cutaneous squamous cell carcinoma (CSCC) is the second most common form of skin cancer caused because of the uncontrolled growth of abnormal squamous cells. Currently, Libtayo is the only approved treatment in the Braz...
Read More >>Parkinson’s Disease is a progressive nervous system disorder that hampers the movement of the body by causing stiffness or slowness. Currently there are no definitive treatments for this clinical condit...
Read More >>Prostate cancer is one of the leading causes of deaths among men in the U.S. On an average, 1 out of 9 men are diagnosed with prostate cancer in their lifetime. Currently, there are several treatments which can pr...
Read More >>Atopic Dermatitis (AD) is a chronic skin disease characterized by skin barrier defects and inflammation. It results in itching, induration (hardening)/papulation (formulation of papules), and oozing/crusting and affect...
Read More >>Among the most vital treatment breakthrough for cancer patients are therapies that targeted the site of tumors and regimens with novel combinatio...
Read More >>Glaucoma is an eye condition in which fluid pressure builds up within the eye affecting optic nerves. If not treated, a Glaucoma patient might lose partial vision or even go blind. The disease mostly occurs in older ad...
Read More >>There is a substantial rise in the pharmaceutical firms conducting clinical trials to discover new therapies for a plethora of rare diseases. To encourage pharmaceutical firms to intensify their research efforts and to...
Read More >>Glaucoma is a disease that damages a patient’s optic nerve and can eventually lead to blindness if not treated on time. It is currently considered to be the third leading cause of irreversible blindness worldwide...
Read More >>Breast cancer is one of the most prominent cancer types that can occur in women. Though treatment options depend on the stage of the disease, it can be addressed successfully if diagnosed and treated early. Various med...
Read More >>Ovarian cancer occurs when cells in the ovary start to mutate abnormally, further forming a tumor. At late stages, ovarian cancer can become difficult to treat and could also be fatal to patient. Several pharmaceu...
Read More >>The treatment graph for one of the most fatal ailments of the 21st century, the dreaded ‘cancer’, seems to be on the verge of witnessing yet another variable addition. In what may seem as yet ano...
Read More >>Parkinson's disease (PD) is an incurable, progressive neurodegenerative disease which is caused by the death of dopaminergic neurons in the midbrain. With medication, motor symptoms can be treated but it is impossi...
Read More >>Vitiligo is a common disease that causes the patient to lose skin color in random blotches. The disease can affect any body part, even affecting the inside of the patient’s mouth and hair. There are some tre...
Read More >>Cases of inflammatory diseases are expected to increase in the near future, which is a major concern for people across the world. Various pharmaceutical companies as well as medical research organizations are increasin...
Read More >>Breast cancer is the second most common cause of death among women. With rising cases of breast cancer recorded worldwide, the need for developing an effective therapy has become a priority for many pharmaceutical...
Read More >>Leber Hereditary Optic Neuropathy (LHON) is a hereditary form of vision loss that usually begins at teenage or in the early twenties. With few rare cases likely to occur in late adulthood or early childhood, vario...
Read More >>With novel clinical trials, organizations across the world are developing new therapies and next-generation treatment for targeting fatal diseases such as cancer. The result of such clinical trials can aid the improvem...
Read More >>Aesthetic medicine is increasingly being used for the treatment of physical impairments such as skin discoloration, excessive fat, scars, skin laxity, wrinkles, cellulite, and liver spots. Customer are seen demanding f...
Read More >>There is a substantial rise in the number of people affected with pulmonary diseases like asthma. Various pharmaceutical companies in the world are combining their capabilities to find treatments for serious pulmonary ...
Read More >>As cases of neurodegenerative diseases like Alzheimer’s and Parkinson’s are on a rise, biopharmaceutical firms are actively engaging in developing new clinical drugs. Companies are also gaining increased fu...
Read More >>With heart related issues and number of people diagnosed with heart failure increasing substantially, the need to find a solution to this problem is growing considerably. Advanced technology, equipment and pharmaceutic...
Read More >>Patients having Relapsed-refractory multiple myeloma (RRMM) along with extramedullary disease (EMD) will be treated by Oncopeptides AB. In the comp...
Read More >>As part of the 5-year agreement, Vertex will also be collecting real world data on these medicines. Vertex Pharmaceuticals Incorporated has reportedly announced tha...
Read More >>Grünenthal will own the exclusive commercialization rights of allogeneic cell therapy candidate MPC-06-ID in Latin America and Europe. Grünenthal, a pharm...
Read More >>IN.PACT AV DCB showed encouraging results in the treatment of AV Fistulae Lesions in Renal Disease Patients at its last stage. Medtronic plc, one of the world&rsquo...
Read More >>12 patients with DME have enrolled into the study. The results for the Phase 1 trial will be out by the end of 2019. ...
Read More >>The ORION-11 trial of inclisiran sodium 300 mg reached all secondary and primary endpoints with efficacy that is consistent with the findings from Phase 2 and 1 trials. ...
Read More >>Atrium Spectrum Disorder (ASD) affects 1 in 59 school children of 8-years in the United States. It is a common neurodevelopmental disorder, with a higher level of heterogeneity. ...
Read More >>Health population initiatives will be powered by Fitbit wearable devices and new Premium service Fitbit Inc., a San Francisco based tech company, has announced that...
Read More >>The company announced positive results from its Phase 3 CONFIRM trial of terlipressin in Hepatorenal Syndrome Type 1. The study verified HRS-1 reve...
Read More >>Sonnet proposes to pay 7,111,947 common shares and outstanding common stocks to Relief Therapeutics. Sonnet BioTherapeutics, Inc., a biotechnology company that deve...
Read More >>Versant Ventures’ portfolio company, Bluerock Therapeutics acquired by Bayer AG for approximately USD 1 billion. This acquisition represents ...
Read More >>Stable vision was achieved in 99.2% of subjects under the OPT-302 (2.0 mg) combination treatment, compared to 96.7% from the Lucentis control group at primary endpoint ...
Read More >>Six patients will be registered for the trial and will be treated with ELX-02 for four weeks with three rising dose levels. Eloxx Pharmaceuticals, Inc., an American...
Read More >>The study involved around 139 subjects who had reported four or more episodes of herpes labialis in the past 12 months Squarex, a clinical-stage pharmaceutical comp...
Read More >>Data will be demonstrated at an upcoming medical meeting and shared with health authorities globally, including the U.S. FDA (Food and Drug Administration). Genentech, a subsidiary ...
Read More >>Brainscope has announced the successful completion of its nearly five year research contract with United States Department of Defense. The contract worth $9.9 million was to support the development and validation of an...
Read More >>The trial is designed to assess the efficacy and safety of OC-01 for treating dry eye disease Reports confirm that Oyster Point Pharma, a clinical-stage biopharmac...
Read More >>Ligand is eligible to receive royalties and milestones depending on potential future sales Ligand Pharmaceuticals Incorporated, a biopharmaceutical company focused ...
Read More >>PharmHouse’s greenhouse facility in Ontario is reportedly one of the largest in the world Canopy Rivers Inc, Canopy Growth Corp’s venture capital arm, h...
Read More >>High income-growth countries like China will be the key recipient of the Detraxi biotechnology. Detraxi, a biotechnology company, is reportedly planning to develop ...
Read More >>LifeMax Laboratories Inc a subsidiary of LifeMax Healthcare International Corporation, recently announced that a Novartis licensed investigational therapy, LM-030, has been granted pediatric disease designation by the FD...
Read More >>The company has been looking forward to initiate larger phase 2 trials. The clinical-stage company Athira Pharma, Inc. has reportedly announced preliminary data fro...
Read More >>APG-2575 created by Ascentage Pharma is one of the rare Bcl-2 selective inhibitors in active clinical studies apart from Venetoclax. Ascentage Pharma has repor...
Read More >>Ibudilast could be the best-in-disease drug for MS patients with unmet medical needs MediciNova, Inc., a biopharmaceutical company that develops novel therapeutics ...
Read More >>The teaming up of CMIC with other companies will improve the collaboration and execution of clinical studies CMIC Group, a leading Japanese Contract Research Organization (CRO) that provides complete range of pharmaceutica...
Read More >>The data validates AMT-061 to be well-tolerated and capable of increasing FIX activity to normal in patients with hemophilia B. Renowned gene therapy firm, uniQure ...
Read More >>All the 20 patients for the monotherapy arm of the trial have begun treatment with 10 mg/kg dosage level Swedish biotech firm Cantargia has reportedly announced ful...
Read More >>Gilead Sciences, Inc., a biotechnology company recently provided an update about the investigational- filgotinib, selective JAK1 inhibitor, at a pre-NDA (New Drug Application) meeting with the USFDA, cite sources. ...
Read More >>The partnership will bring the best first-in-class therapeutics and diagnostics for patients around the world PeptiDream, a public biopharmaceutical company that is...
Read More >>American biopharmaceutical firm AbbVie Inc has reportedly announced its decision to acquire Botox-maker Allergan Plc in a $63 billion deal. Apparently, this move would hand over the...
Read More >>Galactosemia patients are in urgent need of treatment options and the company is committed to advancing AT-007 through clinical development Reports confirm that App...
Read More >>Phase 1/2a trial of RBM-007 was successfully conducted, yielding top-line results Seven out of nine subjects showed a considerable im...
Read More >>Editas Medicine Inc., a U.S.-based pharmaceutical company recently announced results from trial of two different CRISPR-Cas9 genome editing strategies, one targeting the beta-globin locus and the other targeting the er...
Read More >>Hemispherx Biopharma Inc., a US-based biopharmaceutical company recently announced having treated its first patient with Ampligen in combination with Cisplatin & Pembrolizumab, in a phase 2 ovarian cancer clinical ...
Read More >>The firm’s drug (HMI-102) is expected to be the first gene therapy candidate for phenylketonuria (PKU) to enter clinics. Genetic drug maker, Homology Medicine...
Read More >>Next-generation Guardian CGM is designed to lower sensor calibrations, improve and refine the accuracy and the overall performance of the system World’s large...
Read More >>Cellenkos Inc., an early stage clinical biotechnology company recently announced initiation of Phase 1 clinical trial of CK0801 for treatment of bone marrow failure syndromes, including primary myelofibrosis, hypoplast...
Read More >>The French multinational pharmaceutical company Sanofi has reportedly announced crucial Phase 3 ICARIA-MM trial results which revealed that isatuximab aided with dexamethasone and pomalidomide (isatuximab combination t...
Read More >>The data revealed Moderna’s mRNA personalized cancer vaccine (PCV) mRNA-4157 to be well-tolerated at all tested doses and elicited neoantigen-specific T-cell responses. ...
Read More >>Novartis has recently unveiled the first clinical trial results from the phase III PLATINUM clinical development program evaluating the efficacy and safety of QMF149, which is an investigational, once a day, fixed dose...
Read More >>Mesoblast Limited has reportedly filed a rolling submission for Biologics License Application with the U.S Food and Drug Administration for remestemcel-L to treat steroid-refractory acute graft versus host disease in c...
Read More >>A regenerative medicine company Rexgenero, creating advanced cell-based therapies for the treatment of critical limb ischaemia, has reportedly expanded the production of its lead development therapy REX-001 by partneri...
Read More >>The company plans to initiate Phase III trials to assess mirikizumab’s benefit-risk profile to cure Crohn’s disease. U.S. pharma giant, Eli Lilly and Co...
Read More >>The acquisition would help Merck strengthen its presence in the renal cell carcinoma space and support its cancer drug portfolio. U.S. pharmaceutical conglomerate, ...
Read More >>Sublingual administration of BXCL501 had achieved drug exposures that will be therapeutic for the acute treatment of agitation Reports confirm that BioXcel Therapeu...
Read More >>A multi-centre phase-two study will represent the fourth clinical trial ongoing for Kazia’s GDC-0084 drug candidate Kazia Therapeutics Ltd, an Australian onco...
Read More >>GSK anticipates using Zymeworks’ Azymetric technology for developing bispecifics drugs that treat communicable diseases Zymeworks Inc, a clinical-stage biopha...
Read More >>Vertex would be paying $70 million in advance to work with Kymera including an equity investment in the company Kymera Therapeutics and Vertex Pharmaceuticals Incor...
Read More >>Roche, the leading Swiss pharma has pushed back its scheduled acquisition of the gene therapy specialist, Spark Therapeutics for third time in a row, as it waits for the U.S. government to complete regulatory review of...
Read More >>Condiments and sauce manufacturer Veeba Foods reportedly ventured into child nutrition segment with a new health beverage, V-Nourish. According to sources close to the matter, V-Nou...
Read More >>In May the drug received FDA breakthrough status and had lowered the risk of death for patients by 30% as compared to placebo The U.S. Food and Drug Administration ...
Read More >>FORTITUDE-ALS did not attain statistical importance in its primary endpoint of change from baseline in SVC Patients who received reldesemtiv in FORTITUDE-AL...
Read More >>The latest study will assess Apristor’s safety plus pharmacological profile in patients, besides the biomarker analyses, for exploring the drug’s predictive response factors. ...
Read More >>The leading American AAV-based genetic medicines company, Audentes Therapeutics Inc., has reportedly presented new positive data from ASPIRO, the AT132 Phase 1/2 clinical trial for the treatment of XLMTM (X-linked Myot...
Read More >>In a recent turn of events, Norton Healthcare and Select Medical have reportedly declared signing a joint venture agreement intended to assimilate outpatient rehabilitation solutions in the Southern Indiana and Louisville metro provinces. ...
Read More >>Bicycle Therapeutics, a biotech firm pioneering a new therapeutic class based on its patented bicyclic peptide or Bicycle® platform, and Oxurion have recently declared complete registration of Oxurion’s Phase...
Read More >>Precision is creating PBCAR0191 in partnership with Servier, a multinational pharmaceutical firm The company believes that the patien...
Read More >>BioTime Incorporation, a clinical stage biotechnology firm developing newfangled cellular treatments, has recently declared that updated outcomes from a Phase I/IIa clinical study of OpRegen®, its chief product can...
Read More >>Plenity is has been cleared for obese or overweight adults having a body mass index of at least 25 Reports confirm that the U.S. Food and Drug Administration (FDA) ...
Read More >>The data received to date is directionally correct and reduction in HBeAg and HBsAg have been observed in some individuals in both studies. U.S. based clinical-stag...
Read More >>Inscripta is working to develop a full suite of gene-editing tools (reagents, software and instruments) to increase the efficiency and speed of CRISPR-based gene-editing ...
Read More >>· The data was presented at the American Association for Cancer Research Annual Meeting 2019 · ...
Read More >>Clinical-stage biotechnology company Imvax, Inc., committed to creating novel patient-specific vaccines and immunotherapy strategies, has reportedly attained positive results from an ongoing Phase 1b clinical trial tha...
Read More >>Partners Healthcare has now become the first healthcare network to have the tool immediately available to doctors at the point-of-care in Massachusetts. Partners He...
Read More >>Nightstar’s agreement with Biogen will give the company the platform and resources it needs to expand its mission to restore sight in patients with inherited retinal diseases. ...
Read More >>The company is apparently looking to buy the electronic materials maker for bolstering its Performance Materials division Merck KGaA, the laboratory supplies provid...
Read More >>© 2024 ReportsGO.com. All Rights Reserved.